Format

Send to

Choose Destination
Therapie. 2007 Mar-Apr;62(2):99-103. Epub 2007 Jun 21.

[Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines].

[Article in French]

Author information

1
Département d'Oncopharmacologie-Pharmacogénétique, INSERM U564, Centre Régional de Lutte Contre le Cancer Paul Papin, 2 rue Moll, 49033 Angers Cedex 9, France. e.gamelin@unimedia.fr

Abstract

Numerous toxic side-effects, sometimes severe, are regularly reported in patients treated with 5-fluorouracil, and oral fluoropyrimidines, UFT and capecitabine, in metastatic and adjuvant setting. These toxic effects are due to a large interindividual variability of the metabolism, mainly depending on dihydropyrimidine dehydrogenase activity (DPD), the major enzyme of the catabolism of fluoropyrimidines. Thus, the patients with a DPD deficiency are at high risk of early severe acute toxicity, with this kind of drug. These toxic side-effects are potentially lethal. DPD deficiency frequencies, partial or complete, are about 3-5% and 0.2% respectively. They are most often due to a gene polymorphism. Different techniques for the detection of DPD deficiency before treatment have been reported: phenotypic, such as the plasma ratio of dihydrouracil/uracil, or genotypic, such as the detection of DPD gene variants, deleterious for enzyme activity. The pretherapeutic detection of DPD deficiency would permit to avoid almost every early acute toxic side-effects. We must emphasize that it is not merely a genetic result, since the detection of a deficiency most often does not contra-indicate the use of a fluoropyrimidine, but it must be combined with therapeutic advice.

PMID:
17582309
DOI:
10.2515/therapie:2007023
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center